Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

  • Showing results for a modified search because your search retrieved no results.
1.

What can be learnt about disease progression in breast cancer dormancy from relapse data?

Willis L, Graham TA, Alarcón T, Alison MR, Tomlinson IP, Page KM.

PLoS One. 2013 May 6;8(5):e62320. doi: 10.1371/journal.pone.0062320. Print 2013.

2.

Breast cancer dormancy can be maintained by small numbers of micrometastases.

Willis L, Alarcón T, Elia G, Jones JL, Wright NA, Tomlinson IP, Graham TA, Page KM.

Cancer Res. 2010 Jun 1;70(11):4310-7. doi: 10.1158/0008-5472.CAN-09-3144. Epub 2010 May 25.

3.

A quantitative insight into metastatic relapse of breast cancer.

Hanin L, Pavlova L.

J Theor Biol. 2016 Apr 7;394:172-181. doi: 10.1016/j.jtbi.2016.01.014. Epub 2016 Jan 19.

PMID:
26801873
4.

Dormancy and surgery-driven escape from dormancy help explain some clinical features of breast cancer.

Retsky MW, Demicheli R, Hrushesky WJ, Baum M, Gukas ID.

APMIS. 2008 Jul-Aug;116(7-8):730-41. doi: 10.1111/j.1600-0463.2008.00990.x. Review.

PMID:
18834415
5.

Reconstruction of the natural history of metastatic cancer and assessment of the effects of surgery: Gompertzian growth of the primary tumor.

Hanin L, Bunimovich-Mendrazitsky S.

Math Biosci. 2014 Jan;247:47-58. doi: 10.1016/j.mbs.2013.10.010. Epub 2013 Nov 6.

PMID:
24211826
6.

[Establishment of animal model of breast cancer dormancy].

Su GY, Liu YQ, Ren LR, Liu XF, Gu B, Dong JH, Gao J.

Zhonghua Bing Li Xue Za Zhi. 2007 Nov;36(11):760-3. Chinese.

PMID:
18307882
7.

Metastasis dormancy in estrogen receptor-positive breast cancer.

Zhang XH, Giuliano M, Trivedi MV, Schiff R, Osborne CK.

Clin Cancer Res. 2013 Dec 1;19(23):6389-97. doi: 10.1158/1078-0432.CCR-13-0838. Review.

8.
9.

Who should not undergo breast conservation?

Nijenhuis MV, Rutgers EJ.

Breast. 2013 Aug;22 Suppl 2:S110-4. doi: 10.1016/j.breast.2013.07.021. Review.

PMID:
24074770
10.

Association between developmental steps in the organogenesis of the uterine cervix and locoregional progression of cervical cancer: a prospective clinicopathological analysis.

Höckel M, Hentschel B, Horn LC.

Lancet Oncol. 2014 Apr;15(4):445-56. doi: 10.1016/S1470-2045(14)70060-9. Epub 2014 Mar 19.

PMID:
24656439
11.

Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival.

Tobin NP, Harrell JC, Lövrot J, Egyhazi Brage S, Frostvik Stolt M, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Walz T, Fernö M, Perou CM, Bergh J, Hatschek T, Lindström LS; TEX Trialists Group.

Ann Oncol. 2015 Jan;26(1):81-8. doi: 10.1093/annonc/mdu498. Epub 2014 Oct 31.

12.

Ipsilateral breast tumor recurrence as a predictor of distant disease: implications for systemic therapy at the time of local relapse.

Haffty BG, Reiss M, Beinfield M, Fischer D, Ward B, McKhann C.

J Clin Oncol. 1996 Jan;14(1):52-7.

PMID:
8558220
13.

Tumour dormancy: findings and hypotheses from clinical research on breast cancer.

Demicheli R.

Semin Cancer Biol. 2001 Aug;11(4):297-306. Review.

PMID:
11513565
14.

Recurrence dynamics does not depend on the recurrence site.

Demicheli R, Biganzoli E, Boracchi P, Greco M, Retsky MW.

Breast Cancer Res. 2008;10(5):R83. doi: 10.1186/bcr2152. Epub 2008 Oct 9.

15.

[Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].

Wojtacki J, Kruszewski WJ, Sliwińska M, Kruszewska E, Hajdukiewicz W, Sliwiński W, Rolka-Stempniewicz G, Góralczyk M, Leśniewski-Kmak K.

Przegl Lek. 2001;58(6):498-503. Polish.

PMID:
11816740
16.

Tumor dormancy and cancer stem cells: two sides of the same coin?

Kleffel S, Schatton T.

Adv Exp Med Biol. 2013;734:145-79. doi: 10.1007/978-1-4614-1445-2_8.

PMID:
23143979
17.
18.

Outpatient follow-up after treatment for early breast cancer: updated results after 5 years.

Churn M, Kelly V.

Clin Oncol (R Coll Radiol). 2001;13(3):187-94.

PMID:
11527293
19.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
20.

Evidence to support a change in follow-up policy for patients with breast cancer: time to first relapse and hazard rate analysis.

Wheeler T, Stenning S, Negus S, Picken S, Metcalfe S.

Clin Oncol (R Coll Radiol). 1999;11(3):169-73.

PMID:
10465470

Supplemental Content

Support Center